Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Steroid treatment associated with earlier onset of adverse events in children with biliary atresia

This week's publication of the Journal of the American Medical Association investigates the use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia.

News image

Biliary atresia is the most common cause of end-stage liver disease in children.

Controversy exists as to whether use of steroids after hepatoportoenterostomy improves clinical outcome.

Dr Jorge Bezerra and colleagues determined whether the addition of high-dose corticosteroids after hepatoportoenterostomy is superior to surgery alone in improving biliary drainage and survival with the native liver.

The research team performed a multicenter, double-blind Steroids in Biliary Atresia Randomized Trial (START) in 140 infants between 2005 and 2011 in the United States.

The team's follow-up ended in January 2013.

Transplant-free survival was about 59% in the steroids group
Journal of the American Medical Association

Participants were randomized to receive intravenous methylprednisolone, and oral prednisolone followed by a tapering protocol for 9 weeks or placebo initiated within 72 hours of hepatoportoenterostomy.

The team's primary end point was the percentage of participants with a serum total bilirubin level of less than 1.5 mg/dL with his/her native liver at 6 months posthepatoportoenterostomy.

Secondary outcomes included survival with native liver at 24 months of age and serious adverse events.

The researchers found that proportion of participants with improved bile drainage was not statistically significantly improved by steroids at 6 months posthepatoportoenterostomy of placebo group.

The team observed that the adjusted absolute risk difference was 9%.

Transplant-free survival was about 59% in the steroids group, and in the placebo group at 24 months of age.

The team noted that the percentage of participants with serious adverse events was 81% of the steroids group, and 80% of the placebo group.

However, participants receiving steroids had an earlier time of onset of their first serious adverse event by 30 days posthepatoportoenterostomy.

Dr Bezerra's team concludes, "Among infants with biliary atresia who have undergone hepatoportoenterostomy, high-dose steroid therapy following surgery did not result in statistically significant treatment differences in bile drainage at 6 months, although a small clinical benefit could not be excluded."

"Steroid treatment was associated with earlier onset of serious adverse events in children with biliary atresia."

JAMA 2014;311(17):1750-1759
08 May 2014

Go to top of page Email this page Email this page to a colleague

 28 August 2015

Advanced search
 28 August 2015 
Statin use and survival in pancreatic cancer
 28 August 2015 
Bacterial endotoxin and NAFLD
 28 August 2015 
Interferon-free regimens for Hep C
 27 August 2015 
HCV in Egypt
 27 August 2015 
Gene expression for hepatocellular carcinoma
 27 August 2015 
Liver abnormalities in celiac disease
 26 August 2015 
Medical management of diverticular disease
 26 August 2015 
Treatment of erosive esophagitis
 26 August 2015 
Dermatological complications of anti-TNF therapy in IBD
 25 August 2015 
Markers for colorectal cancer screening
 25 August 2015 
Long-term PPI use and serum gastrin levels
 25 August 2015 
Treatment for HCV and HIV-1 co-infection
 24 August 2015 
Treatment for HCV and HIV-1 co-infection
 24 August 2015 
Cirrhosis in Hepatitis C patients
 24 August 2015 
Aspirin use and colorectal cancer survival
 21 August 2015 
Activity indexes in ulcerative colitis
 21 August 2015 
Coffee and gallstone disease
 21 August 2015 
Alcoholic cirrhosis in relapse after liver transplant
 20 August 2015 
Cirrhosis in the USA
 20 August 2015 
Mortality causes in liver cirrhosis
 20 August 2015 
Risk of death in IBD
 19 August 2015 
Predicting intestinal surgery in Crohn's disease
 19 August 2015 
Improved screening colonoscopy quality
 19 August 2015 
Sleep positioning device reduces reflux
 18 August 2015 
Health insurance influences HCV screening outcomes
 18 August 2015 
Somatostatin analogues in polycystic liver disease
 18 August 2015 
Global consensus report on H. pylori gastritis
 17 August 2015 
Biomarker of fibrosis stage in NAFLD
 17 August 2015 
Prognostic score for primary biliary cirrhosis
 17 August 2015 
Measuring subjective health in patients with IBS
 14 August 2015 
Factors that influence ulcerative colitis procedure type
 14 August 2015 
H. pylori in African American and Hispanic veterans
 14 August 2015 
Hep E virus in decompensated chronic liver disease
 13 August 2015 
H. pylori in drinking water
 13 August 2015 
Sofosbuvir-regimens in HCV
 13 August 2015 
IBS among Japanese adolescents
 12 August 2015 
Infliximab in patients in IBD
 12 August 2015 
Peritoneal carcinomatosis in colorectal cancer
 12 August 2015 
Predictors of severity of IBD
 11 August 2015 
H. pylori and immune thrombocytopenic purpura
 11 August 2015 
Chemotherapy and intestinal microbiomes
 11 August 2015 
Sexual dysfunction after rectal cancer treatment
 10 August 2015 
Scoring systems to predict alcoholic hepatitis outcomes
 10 August 2015 
Sofosbuvir-based regimens in veterans with HCV
 10 August 2015 
Predicting lymph node metastasis in T1 colorectal cancer
 07 August 2015 
Factors associated with changes in ulcerative colitis
 07 August 2015 
Bariatric surgery and NASH in obese patients
 07 August 2015 
Caffeine and fibrosis in Hep C
 06 August 2015 
Disparities in colonoscopic examination
 06 August 2015 
Weight loss and NASH
 06 August 2015 
Diagnosis of IBS
 05 August 2015 
Gender differences in fecal immunochemical tests
 05 August 2015 
Adenoma detection rates with a screening colonoscopy program
 05 August 2015 
Extraintestinal manifestations in IBD diagnosis
 04 August 2015 
IBD environmental risk factors
 04 August 2015 
Measuring disease activity in Crohn's
 04 August 2015 
Gastric emptying and hyperglycemia in diabetes
 03 August 2015 
Vaccinations and IBD
 03 August 2015 
Lack of response to therapy in severe ulcerative colitis
 03 August 2015 
Nutritional vs biological therapy in Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us